CN110898111A - Plaster for treating bone rheumatism and preparation method thereof - Google Patents
Plaster for treating bone rheumatism and preparation method thereof Download PDFInfo
- Publication number
- CN110898111A CN110898111A CN201911322313.8A CN201911322313A CN110898111A CN 110898111 A CN110898111 A CN 110898111A CN 201911322313 A CN201911322313 A CN 201911322313A CN 110898111 A CN110898111 A CN 110898111A
- Authority
- CN
- China
- Prior art keywords
- emplastrum
- mixture
- mass
- prepared
- volatile oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 27
- 239000011505 plaster Substances 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title claims description 10
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 8
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 8
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 8
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 8
- 241000195954 Lycopodium clavatum Species 0.000 claims abstract description 8
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 8
- 244000203593 Piper nigrum Species 0.000 claims abstract description 8
- 235000008184 Piper nigrum Nutrition 0.000 claims abstract description 8
- 235000013614 black pepper Nutrition 0.000 claims abstract description 8
- 239000001931 piper nigrum l. white Substances 0.000 claims abstract description 8
- 241000173529 Aconitum napellus Species 0.000 claims abstract 2
- 239000000341 volatile oil Substances 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 43
- 239000000843 powder Substances 0.000 claims description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000002674 ointment Substances 0.000 claims description 25
- 239000000706 filtrate Substances 0.000 claims description 20
- 238000010438 heat treatment Methods 0.000 claims description 18
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 17
- 229920002125 Sokalan® Polymers 0.000 claims description 17
- 229960001631 carbomer Drugs 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 17
- 239000012153 distilled water Substances 0.000 claims description 16
- 235000011187 glycerol Nutrition 0.000 claims description 14
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 14
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 11
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 11
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 11
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 5
- 239000004745 nonwoven fabric Substances 0.000 claims description 4
- 238000003892 spreading Methods 0.000 claims description 4
- 230000007480 spreading Effects 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 37
- 208000002193 Pain Diseases 0.000 abstract description 20
- 230000036407 pain Effects 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 17
- 208000024891 symptom Diseases 0.000 abstract description 16
- 230000008961 swelling Effects 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 6
- 240000000249 Morus alba Species 0.000 abstract description 5
- 235000008708 Morus alba Nutrition 0.000 abstract description 5
- 210000002435 tendon Anatomy 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 15
- 208000006820 Arthralgia Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 206010042674 Swelling Diseases 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 210000001503 joint Anatomy 0.000 description 8
- 229920000858 Cyclodextrin Polymers 0.000 description 7
- 208000000114 Pain Threshold Diseases 0.000 description 7
- 230000037040 pain threshold Effects 0.000 description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 235000008216 herbs Nutrition 0.000 description 5
- 206010014025 Ear swelling Diseases 0.000 description 4
- 206010034464 Periarthritis Diseases 0.000 description 4
- 229960001193 diclofenac sodium Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000007939 sustained release tablet Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000227129 Aconitum Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 208000034783 hypoesthesia Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 210000000323 shoulder joint Anatomy 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 240000006432 Carica papaya Species 0.000 description 2
- 235000009467 Carica papaya Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000012287 Prolapse Diseases 0.000 description 2
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 2
- 241000340661 Stauntonia chinensis Species 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 208000036319 cervical spondylosis Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000005801 spondylosis Diseases 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The emplastrum for treating the bone rheumatism is prepared from 10-14 parts by mass of myrrh, 6-10 parts by mass of safflower, 6-10 parts by mass of white pepper, 6-10 parts by mass of monkshood, 22-26 parts by mass of lycopodium clavatum and 14-18 parts by mass of mulberry twigs, and the six medicines are all traditional Chinese medicine raw materials, so that various bone rheumatism can be effectively treated by improving the obstruction of qi and blood stagnation of the bone rheumatism and strengthening the nourishing of tendon and vessel joints. The Chinese medicinal raw materials are prepared into emplastrum, and the emplastrum is directly applied to the sore swelling and pain part of a patient to improve the symptoms of bone impediment.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a plaster for treating bone rheumatism and a preparation method thereof.
Background
Bone bi-arthralgia is one of five-body bi-arthralgia, which is a limb bi-arthralgia disease mainly manifested by heaviness, numbness and weakness of limbs, pain and swelling of bone and joints, stiff and deformed joints and limited movement of bones and joints due to the fact that wind-cold-dampness pathogen keeps the muscles and joints of human body for a long time, and the qi and blood of meridians are blocked, or old people are aged and physically weak, and bones are lost to nourish and bone are weak. Is equivalent to the bone injury arthralgia such as rheumatoid arthritis, lumbar intervertebral disc protrusion, ankylosing spondylitis, scapulohumeral periarthritis and the like in modern medicine. Its pathogenesis is caused by obstruction of qi and blood and failure of nourishing tendons, vessels and joints.
The traditional western medicine treatment means comprise oral non-steroidal anti-inflammatory analgesic drugs, oral glucosamine and intra-articular injection of sodium hyaluronate, the patients with serious symptoms need joint cleaning or joint replacement, but the western medicine treatment cost is high, the cause of the disease is still not very clear in western medicine, and compared with the symptomatic treatment in western medicine, the traditional Chinese medicine considers that qi-blood obstruction is not smooth and the tendon and vessel joints are not nourished by soft tissue as the main pathogenesis.
Disclosure of Invention
In view of the above, there is a need for a method for preparing a patch for treating arthromyodynia using a pharmaceutical composition.
Also provides a plaster for treating the bone rheumatism by using the pharmaceutical composition.
A preparation method of a emplastrum for treating bone rheumatism is characterized by comprising the following steps: the method comprises the following steps:
(1) taking 10-14 parts by mass of myrrh, 6-10 parts by mass of safflower, 6-10 parts by mass of white pepper, 6-10 parts by mass of radix aconiti, 22-26 parts by mass of lycopodium clavatum and 14-18 parts by mass of ramulus mori, drying, uniformly mixing and crushing into particles of 10-14 meshes to obtain mixed raw materials;
(2) adding distilled water in a predetermined proportion into the mixed raw materials to obtain a prepared mixture, placing the prepared mixture in an extractor, heating to slightly boil, extracting volatile oil, and taking the residual liquid-residue mixture;
(3) filtering the liquid residue mixture to obtain residue, adding ethanol into the residue, reflux-extracting, and filtering to obtain filtrate;
(4) putting the filtrate into a round-bottom flask, installing the round-bottom flask on a rotary evaporator, starting the rotary evaporator to evaporate the filtrate in the round-bottom flask, evaporating the filtrate to form a thick extract, drying the ethanol in the extract, putting the dried extract into an oven, drying, and pulverizing into fine powder to obtain medicinal powder;
(5) mixing the powder with matrix at a predetermined ratio to obtain patch.
Preferably, the mass ratio of the myrrh, the safflower, the white pepper, the monkshood, the lycopodium clavatum and the mulberry twig in the step (1) is 3:2:2:2:6: 4.
Preferably, the step (2) is specifically: adding distilled water with the volume 10 times of the mixed raw materials into the mixed raw materials, soaking for 1 hour to obtain a prepared mixture, placing the prepared mixture into an extractor, heating to slightly boil, extracting volatile oil for 10 hours, and taking the residual liquid-residue mixture.
Preferably, the step (3) is specifically: filtering the medicinal liquid to obtain residue, adding 85% ethanol (6 times of the residue), extracting under reflux for 3 hr, and filtering to obtain filtrate.
Preferably, the step (4) is specifically: putting the filtrate into a round-bottom flask, installing the round-bottom flask on a rotary evaporator, starting the rotary evaporator to evaporate the filtrate in the round-bottom flask, evaporating the filtrate to form a thick extract, volatilizing ethanol in the prepared extract, putting the volatilized ethanol prepared extract into a 65 ℃ oven, drying for 48-72 hours, taking out, and crushing into fine powder to obtain the medicinal powder.
Preferably, the step (5) is specifically: taking glycerol, sodium polyacrylate, carbomer and sodium carboxymethylcellulose in predetermined amounts, heating and melting the glycerol and the sodium polyacrylate in water at 70-80 ℃ in a water bath, slowly adding the sodium carboxymethylcellulose, stirring and grinding uniformly to obtain a matrix; mixing carbomer with distilled water to fully swell carbomer to obtain adjuvants; adding distilled water into the medicinal powder, and heating to obtain soft extract; slowly pouring the prepared ointment and auxiliary materials into the matrix to be mixed to obtain a mixture, putting the mixture into water with the temperature of 70-80 ℃ to carry out water bath heating and melting, stopping heating after the mixture is fully and uniformly stirred, and stirring the mixture into an ointment state again to obtain the emplastrum.
Preferably, the weight of the glycerin is 2-4 g, the weight of the sodium polyacrylate is 0.4-0.6 g, the weight of the carbomer is 0.1-0.2 g, the weight of the sodium carboxymethyl cellulose is 4g, the weight of the predetermined amount of distilled water is 4g, and the weight of the medicinal powder is 1 g.
Preferably, in the step (5), "stirring the mixture again to form an ointment to obtain the emplastrum" specifically comprises: and (3) stirring the mixture into an ointment state again, taking the volatile oil extracted in the step (4), adding all the volatile oil into the ointment at one time, stirring again to fully and uniformly mix the ointment and the volatile oil to obtain a plaster, and spreading the plaster on a non-woven fabric to obtain the plaster.
The invention also provides a emplastrum which is prepared by the preparation method.
By adopting the technical scheme, the invention has the beneficial effects that: myrrh, safflower, white pepper, monkshood, lycopodium clavatum and mulberry twig are all traditional Chinese medicine raw materials, can effectively improve various bone rheumatism symptoms by improving the qi-blood obstruction of the bone rheumatism and strengthening the soft-nourishing of tendons, vessels and joints, and the traditional Chinese medicine raw materials are prepared into emplastrum which is directly applied to the sore swelling and pain part of a patient to improve the symptoms of the bone rheumatism.
Drawings
FIG. 1 is a schematic diagram showing the effect of different extraction sites of herbs on the analgesic activity of mice in a hot plate experiment.
Detailed Description
The embodiment of the invention provides a preparation method of a emplastrum for treating bone rheumatism, which is characterized by comprising the following steps: the method comprises the following steps:
step S01, taking 12g of myrrh, 8g of safflower, 8g of white pepper, 8g of monkshood, 24g of lycopodium clavatum and 16g of mulberry twigs, drying, uniformly mixing and crushing into 12-mesh particles to obtain mixed raw materials;
step S02, adding distilled water with the volume 10 times of that of the mixed raw materials into the mixed raw materials, soaking for 1 hour to obtain a prepared mixture, placing the prepared mixture into an extractor, heating to slightly boil, extracting volatile oil for 10 hours, and taking the residual liquid-residue mixture;
step S03, filtering the liquid medicine to obtain medicine dregs, adding 85% ethanol into the medicine dregs, wherein the volume of the ethanol is 6 times of that of the medicine dregs, continuously refluxing and extracting for 3 hours, and filtering to obtain filtrate;
step S04, putting the filtrate into a round-bottom flask, installing the round-bottom flask on a rotary evaporator, starting the rotary evaporator to rotatably evaporate the filtrate in the round-bottom flask, rotatably evaporating the filtrate to form a thick extract to obtain a prepared extract, volatilizing ethanol in the prepared extract, putting the volatilized ethanol prepared extract into a 65 ℃ oven, drying for 48-72 hours, taking out, and crushing into fine powder to obtain medicinal powder;
step S05, taking 4g of glycerin, 0.6g of sodium polyacrylate and 4g of sodium carboxymethyl cellulose, heating and melting the glycerin and the sodium polyacrylate in water bath at 70-80 ℃, slowly adding the sodium carboxymethyl cellulose, stirring and grinding uniformly to obtain a matrix;
step S06, taking 0.15g of carbomer, and mixing the carbomer with distilled water to fully swell the carbomer to obtain auxiliary materials;
step S07, adding 4g of distilled water into 1g of the medicinal powder and heating the medicinal powder into thick paste to obtain a preparation ointment;
step S08, slowly pouring the prepared ointment and the auxiliary materials into the matrix to be mixed to obtain a mixture, putting the mixture into water of 70-80 ℃ to be heated and melted in a water bath, stirring the mixture fully and uniformly, stopping heating, stirring the mixture into an ointment state again, adding all the volatile oil into the ointment at one time, stirring again to fully and uniformly mix the ointment and the volatile oil to obtain a emplastrum, and spreading the emplastrum on a non-woven fabric to obtain the plaster.
In another preferred embodiment, step S08 is: slowly pouring the prepared ointment and auxiliary materials into the matrix to be mixed to obtain a mixture, putting the mixture into water with the temperature of 70-80 ℃ to carry out water bath heating and melting, stopping heating after the mixture is fully and uniformly stirred, and stirring the mixture into an ointment state again; putting the volatile oil into a vacuum container, adding a predetermined amount of cyclodextrin into the volatile oil, mixing the volatile oil and the cyclodextrin to prepare a volatile oil-cyclodextrin molecular compound by using a Chinese medicinal volatile oil cyclodextrin inclusion technology, adding all the volatile oil-cyclodextrin molecular compounds into the ointment at one time, stirring again to fully and uniformly mix the ointment and the volatile oil-cyclodextrin molecular compounds to obtain a patch, and spreading the patch on a non-woven fabric to obtain the patch.
The volatile oil is a secondary metabolite in a plant body, and clinical and modern pharmacological studies show that the volatile oil has small molecular weight, strong fat solubility, high bioavailability and rapid absorption and effect taking, can easily penetrate through a biological membrane in the body, and has the anti-inflammatory and analgesic effects. In addition, the volatile oil has the property of easy oxidation and volatilization, so that the method for preparing the volatile oil-cyclodextrin molecular compound is added in the preparation process of the step S08 in another preferred embodiment, so that the oxidation and volatilization of the volatile oil can be inhibited, and the utilization rate of the volatile oil is further improved.
The embodiment of the invention also provides a emplastrum which is prepared by the steps S01-S08.
All the above-mentioned "slight boiling" is the same as the description concept of the general rule for measuring volatile oil in the pharmacopoeia, i.e. the state of liquid just before boiling, i.e. the stage of just starting to generate bubbles and being open and not open.
The characteristics of the traditional Chinese medicine raw materials are described as follows:
myrrh: pungent, bitter and neutral in nature. It enters heart, liver and spleen meridians. Dispel stasis, relieve pain, resolve swelling and promote tissue regeneration. Can be used for treating thoracic obstruction, cardialgia, gastralgia, dysmenorrhea, amenorrhea, rheumatalgia, traumatic injury, carbuncle, swelling, and pyocutaneous disease.
Safflower: blood-activating herbs and pain-relieving herbs. Pungent flavor and warm property, entering meridians: heart meridian entered; the liver meridian. The main functions are activating blood and stimulating the menstrual flow, removing stasis and relieving pain.
White pepper: it has the effects of warming middle-jiao, descending qi, eliminating phlegm, and removing toxic substance.
Radix aconiti: pungent, bitter and hot in property and flavor, with strong toxicity. It enters heart, liver, kidney and spleen meridians. Dispel wind and dampness, warm meridians and alleviate pain. Can be used for treating arthralgia due to wind-cold-dampness, arthralgia, and hernia of cold. Can be used for treating arthralgia due to wind-cold-dampness and arthralgia.
B, common clubmoss herb: pungent and slightly bitter in nature, dispel wind and remove dampness, relax tendons and activate collaterals. Can be used for treating joint pain and difficulty in flexion and extension.
Mulberry twig: mild in nature and taste, slightly bitter, dispelling wind-damp and benefiting joints. Can be used for treating rheumatism, shoulder pain, arm pain, and arthralgia.
First, the best material taking quality test 1 and test group for glycerin, sodium polyacrylate and carbomer in the step S05 are determined
Test group 1: the weight of glycerin is 2g, the weight of sodium polyacrylate is 0.4g, the weight of carbomer is 0.1g, the weight of sodium carboxymethylcellulose is 4g, the weight of distilled water is 4g, and the weight of medicinal powder is 1 g;
test group 2: the weight of glycerin is 3g, the weight of sodium polyacrylate is 0.5g, the weight of carbomer is 0.2g, the weight of sodium carboxymethylcellulose is 4g, the weight of distilled water is 4g, and the weight of medicinal powder is 1 g;
test group 3: the weight of glycerin is 4g, the weight of sodium polyacrylate is 0.6g, the weight of carbomer is 0.15g, the weight of sodium carboxymethylcellulose is 4g, the weight of distilled water is 4g, and the weight of medicinal powder is 1 g.
2. Test materials
A weight (Qingdao Tongxi weight Co., Ltd.), a steel ball (Kangda steel ball Co., Ltd., Shandong province), an inclined plate and a glass plate.
3. Test method
Three test groups are respectively subjected to steps S01-S08 to support three groups of emplastrums, the three groups of emplastrums are compared through the evaluation standards of adhesion, lasting adhesion, skin adhesion and sensory indexes, and the optimal material taking amount of glycerin, sodium polyacrylate and carbomer is selected.
4. Test results
Glycerol: sodium polyacrylate: the preferable proportion of carbomer is 4.0: 0.6: when 0.15 hour, the prepared emplastrum has good skin-sticking property, easy uncovering and pasting, ideal physical properties, flat and smooth paste surface, uniform and consistent color, moderate paste hardness, slight elasticity, comfortable skin surface application, capability of resisting certain external force and good shape retention.
Second, pharmacodynamic test
Mouse hot plate analgesic test (test for determining whether the volatile oil is added into ointment to prepare plaster in step S08, that is, whether the mixing of volatile oil and medicinal powder can achieve optimal analgesic effect)
1. Test materials
(1) Medicine
① group of test drugs
A volatile oil moiety group: the volatile oil obtained in step S02;
alcohol-soluble moiety group: the powder obtained in step S04;
volatile oil + alcohol soluble moiety group: mixing the above volatile oil and medicinal powder to obtain volatile oil 3ml/kg and medicinal powder 3 g/kg;
② Positive control drug group
Positive control drug group 1: diclofenac sodium sustained-release tablets (Nouhua pharmaceutical production, batch number: H10980297)
Positive control drug group 2: compound paracetamol tablets (batch number: H20013003, manufactured by southwest pharmaceutical Co., Ltd.)
③ Chinese medicinal control group
Wild papaya slice (Guangdong peace pharmaceutical industry Co., Ltd., batch No. Z44021242)
④ blank group
(2) Animal(s) production
SPF grade mice, weighing 18-22g, female, 70 (supplied by Ningxia university of medicine laboratory animal center).
2. Testing instrument
YLS-6B intelligent hot plate instrument 3 and test method
(1) Grouping and dosing
After the mice are adaptively fed for three days, the mice are randomly divided into 7 groups, each group comprises 10 mice, the tested drug group is a group for administering 3 different extracted substances, and 3ml/kg of volatile oil, 3g/kg of medicinal powder and 3ml/kg of volatile oil and 3g/kg of medicinal powder are respectively administered; 0.04g/kg of diclofenac sodium sustained-release tablets are given to the positive control drug group 1, and 0.3g/kg of compound acetaminophen tablets are given to the positive control drug group 2; 1.2g/kg of stauntonia chinensis slices are given to a traditional Chinese medicine control group; the blank group was given 1ml of physiological saline.
The above groups were administered by intragastric administration 1 time per day.
(2) Dosing and pain threshold determination
The dose (0.1ml/10g) was determined from the body weight of the mice, and each group was administered by gavage 1 time daily for 7 days continuously, and the hot plate method was used after the last administration: the temperature of an YLS-6B intelligent hot plate instrument is adjusted to 55+0.5 ℃, a mouse is placed on the YLS-6B intelligent hot plate instrument, the foot licking of the mouse is recorded as an index of pain response, 1-time pain threshold value is measured every 0min, 15min, 30min and 60min after the last administration, the foot licking of the mouse is used as the index of pain response, if the pain threshold value reaches 60 seconds, the test is stopped, the mouse is taken out, and the pain threshold value of the mouse is calculated in 60 seconds.
(3) Calculation by statistical method
All the data are used
Statistical analysis was performed using SPSS 20.0 and the pain threshold differences between groups were compared using the t-test between groups.
5. Test results (see Table 1)
TABLE 1 influence of different substances of herbs on pain threshold of heat-stimulated mice
Note: denotes P <0.05(P is probability)
As can be seen from table 1, the pain threshold ratio of the volatile oil + alcohol-soluble fraction group in the heat-stimulated mice was significantly affected (P <0.05) compared to the blank group, the volatile oil fraction group, and the alcohol-soluble fraction group, and thus the analgesic effect was exhibited in the volatile oil + alcohol-soluble fraction group, and the effect was the best, so that the best analgesic effect could be achieved in the patch prepared by adding the volatile oil to the ointment in step S08.
(II) mouse ear swelling method anti-inflammatory test (test for determining whether the volatile oil is added into ointment for preparing emplastrum in step S08, and whether the volatile oil and the medicinal powder are mixed to achieve anti-inflammatory effect)
1. Test materials
(1) Medicine
① group of test drugs
A volatile oil moiety group: the volatile oil obtained in step S02;
alcohol-soluble moiety group: the powder obtained in step S04;
volatile oil + alcohol soluble moiety group: mixing the above volatile oil and medicinal powder to obtain volatile oil 3ml/kg and medicinal powder 3 g/kg;
② Positive control drug group
Positive control drug group 1: diclofenac sodium sustained-release tablets (Nouhua pharmaceutical production, batch number: H10980297)
Positive control drug group 2: compound paracetamol tablets (batch number: H20013003, manufactured by southwest pharmaceutical Co., Ltd.)
③ Chinese medicinal control group
Wild papaya slice (Guangdong peace pharmaceutical industry Co., Ltd., batch No. Z44021242)
④ blank group
(2) Animal(s) production
SPF grade mice, weighing 18-22g, female, 70 (supplied by Ningxia university of medicine laboratory animal center).
2. Testing instrument
XB 220A electronic analytical balance
3. Test method
(1) Grouping and dosing
After the mice are adaptively fed for three days, the mice are randomly divided into 7 groups, each group comprises 10 mice, the tested drug group is a group for administering 3 different extracted substances, and 3ml/kg of volatile oil, 3g/kg of medicinal powder and 3ml/kg of volatile oil and 3g/kg of medicinal powder are respectively administered; 0.04g/kg of diclofenac sodium sustained-release tablets are given to the positive control drug group 1, and 0.3g/kg of compound acetaminophen tablets are given to the positive control drug group 2; 1.2g/kg of stauntonia chinensis slices are given to a traditional Chinese medicine control group; the blank group was given 1ml of physiological saline.
The above groups were administered by intragastric administration 1 time per day.
(2) Dosing and post-inflammatory swelling determination
Determining the dosage (0.1ml/10g) according to the weight of the mouse, carrying out intragastric administration for 1 time per day for each group, continuously administering for 7 days, carrying out administration for 30min after the last administration, smearing dimethylbenzene on the right ear to cause inflammation, taking the left ear as a control, removing the cervical vertebra to kill after half an hour, cutting the same area of the two ears of the mouse by a 7mm puncher, analyzing a balance for weighing, calculating the weight difference of the two ears, namely the swelling degree, and calculating the swelling inhibition rate (%).
(3) Calculation by statistical method
All the data are used
Statistical analysis was performed using SPSS 20.0.
5. Test results (see Table 2)
TABLE 2 influence of different substances of the herbs on acute auricle swelling of mice caused by xylene
Note: denotes P <0.05(P is probability)
As can be seen from Table 2, the alcohol-soluble part group has a significant inhibitory effect on ear swelling of mice caused by xylene (P < 0.05); the volatile oil and alcohol-soluble part group can also inhibit ear swelling of mice caused by xylene, namely has anti-inflammatory effect, so that the emplastrum prepared by adding the volatile oil into the ointment in the step S08 can achieve the anti-inflammatory effect.
In conclusion, the mixture of the volatile oil and the medicinal powder can relieve ear swelling to play a remarkable role in resisting inflammation and diminishing swelling, has a definite analgesic effect, can effectively relieve pain caused by the diseases, and shows that the medicinal composition can be used for treating and preventing bone rheumatism such as scapulohumeral periarthritis, rheumatic arthritis and the like.
Thirdly, the clinical curative effect of the invention is as follows:
1. sample information
From 2016, month 1 to 18, month 12, 970 patients treated by the present invention were outpatients, wherein 407 men, 563 women, 88 years of age with the greatest age, and 13 years of age with the smallest. The clinical data was accumulated as follows (see table 3):
TABLE 3 number of cases of different arthralgia types and their healing
| Arthralgia syndrome type | Number of cases | Recovery method | Is remarkable in that | Is basically effective | Invalidation | High efficiency |
| Scapulohumeral periarthritis | 33 | 32 | 1 | 0 | 0 | 100％ |
| Cervical spondylosis of cervical vertebra | 177 | 110 | 42 | 11 | 14 | 92.09％ |
| Prolapse of lumbar intervertebral disc | 363 | 193 | 89 | 55 | 26 | 92.84％ |
| Stenosis of lumbar spinal canal | 152 | 78 | 29 | 25 | 20 | 86.84％ |
| Primary double knee osteoarthritis | 155 | 80 | 33 | 29 | 13 | 91.61％ |
| Falling pillow | 41 | 32 | 7 | 1 | 1 | 97.56％ |
| Gout | 49 | 22 | 17 | 5 | 5 | 89.80％ |
2. Diagnostic criteria
The specific diagnosis standard of each classification of the arthralgia syndrome in traditional Chinese medicine is taken as a confirmation standard.
3. Standard therapeutic effect (see Table 3)
And (3) healing: clinical symptoms disappear, and the disease does not relapse within one year;
remarkably: symptoms and physical signs are improved, clinical symptoms disappear, but the effect duration is limited, and the symptoms recur within one year;
basically, the method is effective: the symptoms and physical signs are mostly improved, the pain degree is obviously relieved, the pain frequency is reduced, and the pain time is shortened;
and (4) invalidation: the pain symptoms and signs did not change.
4. Method of treatment
The plaster prepared by the invention is externally stuck on a painful part or a corresponding acupuncture point, and can be replaced at proper time according to the disease improvement condition once in 7 to 10 days. During application, if bathing is needed, the patch can be temporarily taken off, the skin is wiped dry after bathing, and the patch is slightly heated and then applied to the original place without reducing the drug effect.
5. Typical cases
Case 1: tan Yufang, 50 years old, retired workers, scapulohumeral periarthritis diagnosed in hospitals, pain appears after a left shoulder is directly blown by cold air of an air conditioner when a patient goes out for 1 week, the left shoulder joint is limited in activity, numbness of upper limbs and dizziness do not exist, symptoms are slightly relieved after self hot compress and physical therapy, the left shoulder joint is still limited in activity and cannot comb one head by self, wind-cold-damp evil qi obstruction of shoulder channels and obstruction of channels and collaterals after the patient is cooled are considered, the plaster prepared by the invention is applied externally, the pain is obviously relieved on the same day, the pain disappears after one treatment course, the shoulder joint activity is obviously improved, and the symptoms are not relapsed after two treatment courses are continuously used.
Case 2: the plaster patch prepared by the invention is externally applied to a bilateral air reservoir and a left shoulder well of a patient after treatment for one course of treatment, the symptoms are obviously relieved, and the patient feels no relapse after continuous use for three courses of treatment by considering the nerve root type cervical spondylosis of the patient.
Case 3: zhou prefecture, age 34, official, hospital diagnosis is prolapse of lumbar intervertebral disc, patient appears lumbago after sitting for a long time, accompanied left lower limb radio-induced pain, numbness and weakness, the symptom is obviously aggravated after catching a cold, it is difficult to stand up, the symptom can be alleviated after lying in bed and rest, because work is busy and has not been treated systematically all the time, buy the external application of GU TONG plaster by oneself, oral analgesic drug therapy, the symptom can be alleviated after treating, but still can't sit for a long time and carry heavy object, attack occasionally, the patient carries out the suggestion of lumbar vertebra CT examination: lumbar disc 4-5 is herniated, and the nerve roots on the left side are obviously compressed. The plaster patch is applied to the lumbar yang-yang deficiency and the kidney-yang deficiency at both sides of a patient after the patient is tired and cooled, the pain symptoms of the waist and the legs are obviously relieved after two treatment courses, and the patient is continuously advised to completely disappear after one treatment course.
The clinical curative effect shows that the traditional Chinese medicine composition can effectively treat the bone rheumatism and has obvious curative effect.
While the invention has been described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention.
Claims (9)
1. A preparation method of a emplastrum for treating bone rheumatism is characterized by comprising the following steps: the method comprises the following steps:
(1) taking 10-14 parts by mass of myrrh, 6-10 parts by mass of safflower, 6-10 parts by mass of white pepper, 6-10 parts by mass of radix aconiti, 22-26 parts by mass of lycopodium clavatum and 14-18 parts by mass of ramulus mori, drying, uniformly mixing and crushing into particles of 10-14 meshes to obtain mixed raw materials;
(2) adding distilled water in a predetermined proportion into the mixed raw materials to obtain a prepared mixture, placing the prepared mixture in an extractor, heating to slightly boil, extracting volatile oil, and taking the residual liquid-residue mixture;
(3) filtering the liquid residue mixture to obtain residue, adding ethanol into the residue, reflux-extracting, and filtering to obtain filtrate;
(4) putting the filtrate into a round-bottom flask, installing the round-bottom flask on a rotary evaporator, starting the rotary evaporator to evaporate the filtrate in the round-bottom flask, evaporating the filtrate to form a thick extract, volatilizing ethanol in the extract, putting the extract into an oven, drying, and pulverizing into fine powder to obtain medicinal powder;
(5) mixing the powder with matrix at a predetermined ratio to obtain patch.
2. The method for preparing the emplastrum for treating rheumatism involving bone according to claim 1, wherein the emplastrum comprises the following steps: in the step (1), the mass ratio of myrrh, safflower, white pepper, monkshood, lycopodium clavatum and ramulus mori is 3:2:2:2:6: 4.
3. The method for preparing the emplastrum for treating rheumatism involving bone according to claim 2, wherein the emplastrum comprises the following steps: the step (2) is specifically as follows: adding distilled water with the volume 10 times of the mixed raw materials into the mixed raw materials, soaking for 1 hour to obtain a prepared mixture, placing the prepared mixture into an extractor, heating to slightly boil, extracting volatile oil for 10 hours, and taking the residual liquid-residue mixture.
4. The method for preparing the emplastrum for treating rheumatism involving bone according to claim 3, wherein the emplastrum comprises the following steps: the step (3) is specifically as follows: filtering the medicinal liquid to obtain residue, adding 85% ethanol (6 times of the residue), extracting under reflux for 3 hr, and filtering to obtain filtrate.
5. The method for preparing the emplastrum for treating rheumatism involving bone according to claim 4, wherein the emplastrum comprises the following steps: the step (4) is specifically as follows: putting the filtrate into a round-bottom flask, installing the round-bottom flask on a rotary evaporator, starting the rotary evaporator to evaporate the filtrate in the round-bottom flask, evaporating the filtrate to form a thick extract, volatilizing ethanol in the prepared extract, putting the volatilized ethanol prepared extract into a 65 ℃ oven, drying for 48-72 hours, taking out, and crushing into fine powder to obtain the medicinal powder.
6. The method for preparing the emplastrum for treating arthromyodynia according to any one of claims 1 to 5, wherein the emplastrum comprises the following steps: the step (5) is specifically as follows: taking glycerol, sodium polyacrylate, carbomer and sodium carboxymethylcellulose in predetermined amounts, heating and melting the glycerol and the sodium polyacrylate in water at 70-80 ℃ in a water bath, slowly adding the sodium carboxymethylcellulose, stirring and grinding uniformly to obtain a matrix; mixing carbomer with distilled water to fully swell carbomer to obtain adjuvants; adding distilled water into the medicinal powder, and heating to obtain soft extract; slowly pouring the prepared ointment and auxiliary materials into the matrix to be mixed to obtain a mixture, putting the mixture into water with the temperature of 70-80 ℃ to carry out water bath heating and melting, stopping heating after fully and uniformly stirring, and stirring the mixture into an ointment state again to obtain the emplastrum.
7. The method for preparing the emplastrum for treating rheumatism involving bone according to claim 6, wherein the emplastrum comprises the following steps: the weight of the glycerin is 2-4 g, the weight of the sodium polyacrylate is 0.4-0.6 g, the weight of the carbomer is 0.1-0.2 g, the weight of the sodium carboxymethyl cellulose is 4g, the weight of the predetermined amount of distilled water is 4g, and the weight of the medicinal powder is 1 g.
8. The method for preparing the emplastrum for treating rheumatism involving bone according to claim 7, wherein the emplastrum comprises the following steps: in the step (5), "stirring the mixture again to an ointment state to obtain the emplastrum" specifically includes: and (3) stirring the mixture into an ointment state again, taking the volatile oil extracted in the step (4), adding all the volatile oil into the ointment at one time, stirring again to fully and uniformly mix the ointment and the volatile oil to obtain a plaster, and spreading the plaster on a non-woven fabric to obtain the plaster.
9. A patch which is prepared by the preparation method of any one of claims 1 to 5 and 7 to 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911322313.8A CN110898111A (en) | 2019-12-20 | 2019-12-20 | Plaster for treating bone rheumatism and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911322313.8A CN110898111A (en) | 2019-12-20 | 2019-12-20 | Plaster for treating bone rheumatism and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110898111A true CN110898111A (en) | 2020-03-24 |
Family
ID=69826703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911322313.8A Pending CN110898111A (en) | 2019-12-20 | 2019-12-20 | Plaster for treating bone rheumatism and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110898111A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316082A (en) * | 2013-06-27 | 2013-09-25 | 华南理工大学 | Jiufen cataplasm and preparation method thereof |
| CN105998223A (en) * | 2016-07-05 | 2016-10-12 | 张阳 | Medicinal liquid for acupuncture and moxibustion for treating herniation of cervical disc and preparation method thereof |
| CN107184919A (en) * | 2016-03-15 | 2017-09-22 | 梁梅林 | A kind of wonderful liniment for controlling scapulohumeral periarthritis |
-
2019
- 2019-12-20 CN CN201911322313.8A patent/CN110898111A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316082A (en) * | 2013-06-27 | 2013-09-25 | 华南理工大学 | Jiufen cataplasm and preparation method thereof |
| CN107184919A (en) * | 2016-03-15 | 2017-09-22 | 梁梅林 | A kind of wonderful liniment for controlling scapulohumeral periarthritis |
| CN105998223A (en) * | 2016-07-05 | 2016-10-12 | 张阳 | Medicinal liquid for acupuncture and moxibustion for treating herniation of cervical disc and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 刘浩: "中药内服外治治疗膝关节骨性关节炎临床观察", 《中国当代医药》 * |
| 邓晓生；等: "蠲痹散瘀膏外敷结合红外线治疗仪治疗老年人膝关节骨性关节炎48例", 《现代医院》 * |
| 邵则训；等: "中药熏洗法在骨伤科的应用", 《内蒙古中医药》 * |
| 陈世雄；等: "综合疗法治疗膝骨性关节炎临床观察", 《中国中医骨伤科杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258658A (en) | Plaster for invigorating blood circulation and relieving pain | |
| CN104815295A (en) | Traditional Chinese medicine preparation for treating cervical spondylosis | |
| CN102600264A (en) | Externally-applied traditional Chinese medical composition for treatment of orthopedic diseases | |
| CN104274546A (en) | Externally-applied traditional Chinese medicine composition, externally-applied traditional Chinese medicine preparation as well as preparation method and application of externally-applied traditional Chinese medicine composition | |
| CN103933129B (en) | Plaster for treating pain | |
| CN109432269A (en) | A kind of Chinese medicine composition and preparation method, purposes | |
| CN104840599A (en) | Medicine for treating ankylosing spondylitis | |
| CN103720851A (en) | Traditional Chinese medicinal decoction for treating osteoproliferation | |
| CN104474108A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and preparation method of traditional Chinese medicine preparation | |
| CN103977367A (en) | Traditional Chinese medicament for treating qi-stagnation blood-aggregation type bedsore and preparation method thereof | |
| CN110898111A (en) | Plaster for treating bone rheumatism and preparation method thereof | |
| CN103585294B (en) | A kind of for plaster treating hyperosteogeny and preparation method thereof | |
| CN102579672A (en) | Medicament for treating bone hyperplasia and lumbar disc herniation | |
| CN102688459B (en) | Traditional Chinese medicine composite for curing cervical spondylosis and preparation method thereof | |
| CN103977260B (en) | A kind of medicine for treating sciatica and preparation method | |
| CN115645503B (en) | Medicinal composition and acupoint application paste for treating chronic pain diseases | |
| CN115120629B (en) | Application of cord grass in preparing medicament for preventing/treating osteoarthropathy, and traditional Chinese medicine composition, traditional Chinese medicine preparation and preparation method thereof | |
| CN101954043A (en) | Medicament for treating hyperosteogeny and preparation method thereof | |
| CN107174625B (en) | Traditional Chinese medicine composition for treating lumbar foreign body sensation after lumbar internal fixation | |
| CN105560537A (en) | Medicine composition for treating osteoartritis and preparation method thereof | |
| CN117085074A (en) | Traditional Chinese medicine composition for treating lumbar disc herniation accompanied by radiculopathy and preparation method thereof | |
| CN104208374A (en) | Medicinal liquor for treating lumbar disc herniation | |
| CN103191340A (en) | Drug for nursing osteochondroma | |
| CN104257792B (en) | For treating sick Chinese medicine composition of numbness and preparation method thereof | |
| CN110840936A (en) | Traditional Chinese medicine composition for treating ankylosing spondylitis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200324 |